Abstract: Objective To evaluate the efficacy and adverse side effects of controlled-release oxycondone in the management of moderate to severe cancer pain in patients with teminal cancer and to observe any improvement on the life quality of cancer patients.Methods Thirty-eight patients with moderate or severe cancer pain were treated with controlled-release oxycondone.The initial dose was 5mg q12h to the cancer patients with moderate pain or 10mg q12h to the cancer patients with severe pain, or 1/2 that of the standard morphine regimen.Results The final titrated dosage of oxycondone was as follows:the patients in 17 cases(44.7%)received a dosage of ≤30mg/d, those in 9 cases(23.7%)received a dosage of 31 to 60mg/d, those in 10 cases(26.3%)received a dosage of 61 to 120mg/d and those in 2 cases(5.3%)received a dosage of ≥120mg/d.The overall rate of relief from pain was 94.7%.The common side effects reported were constipation in 40 cases(65.6%), dizziness in 9 cases(14.7%), nausea in 7 cases(11.5%)and somnolence in 5 cases(8.2%)during controlled-release oxycodone treatment.No patient had respiratory depression.Conclusion The side effects of controlled-release oxycodone are mild, and the drug is effective and safe for the management of cancer patients with moderate to severe pain and can significantly improve the life quality of cancer patients with pain.